SmithKline Beecham’s right to exclusive marketing of a popular pharmaceutical product is under assault by three makers of generic drugs, but SmithKline, which makes the widely prescribed antidepressant Paxil, isn’t letting that get it down.

Arthur Makadon, Jamie B. Bischoff and Sally A. Steffen of Philadelphia’s Ballard Spahr Andrews & Ingersoll, aided by several lawyers from Washington, D.C.’s Finnegan Henderson Farabow Garrett & Dunner, have gone to U.S. District Court in Philadelphia and Chicago to challenge the generic producers’ petitions for accelerated approval of their versions of paroxetine hydrochloride.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]